The first half of 2023 has come to an end, and so far, this year has been just as action-packed as 2022. The first two quarters of the year have been full of first-of-their-kind clinical trials and psychedelic research, new businesses, failed businesses, altered perceptions, and certainly tons of passion. The second quarter, in particular, has been full of breaking news and important developments in the psychedelic sector.  There has been a lot going on in the industry this year. But, if we were to sum up the momentum into one sentence, it would be this: preparation for the commercialization of MDMA. 

You must have PRO to access this content
or purchase this report individually.

Buy Now $499.99